Top

World Journal of Urology

Published in:

01-06-2014 | Topic Paper

Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death

Authors: David Y. T. Chen, Robert G. Uzzo, Rosalia Viterbo

Published in: World Journal of Urology | Issue 3/2014

Abstract

Introduction

The presentation of renal cell carcinoma (RCC) has changed where it is most commonly identified when asymptomatic and incidental. Contemporary patients with renal tumors are often older in age and may have significant concurrent medical comorbidity, where proceeding with routine surgical treatment may not be of benefit. Traditional clinical assessments have not considered the impact of comorbidity on oncologic outcome, and recent studies have demonstrated the relationship between comorbidity and patient survival. We review the existing data examining the significance of medical comorbidity on RCC management and outcomes.

Materials and methods

The existing literature on this topic is reviewed, and validated measures of comorbidity are described. The available studies examining the relationship between comorbidity and RCC are summarized.

Results and Discussion

The article reviews the growing body of literature supporting the importance of assessment of patient comorbidity, and we highlight novel prognostic instruments that can estimate the likelihood of several different patient outcomes following RCC treatment, and these nomograms can be accessed via a web-based portal (www.cancernomograms.com) to assist in patient education and clinical decision making.

Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631PubMedCrossRef

Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1):78–83PubMedCrossRef

Parsons JK, Schoenberg MS, Carter HB (2001) Incidental renal tumors: casting doubt on the efficacy of early intervention. Urology 57(6):1013–1015PubMedCrossRef

Russo P, Jang TL, Pettus JA et al (2008) Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 113(1):84–96PubMedCentralPubMedCrossRef

Gill IS, Kavoussi LR, Lane BR et al (2007) Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178(1):41–46PubMedCrossRef

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18):1331–1334PubMedCrossRef

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2007) Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109(9):1763–1768PubMedCrossRef

Uijen AA, van de Lisdonk EH (2008) Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 14(Suppl 1):28–32PubMedCrossRef

Partnership JR. Chronic conditions: making the case for ongoing care. http://www.partnershipforsolutions.org/DMS

10.

Kassouf W, Aprikian AG, Laplante M, Tanguay S (2004) Natural history of renal masses followed expectantly. J Urol 171(1):111–113 (discussion 113)PubMedCrossRef

11.

Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100(4):738–745PubMedCrossRef

12.

Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431PubMedCrossRef

13.

Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13):2844–2852PubMedCentralPubMedCrossRef

14.

Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118(4):997–1006PubMedCrossRef

15.

Smaldone MC, Uzzo RG (2011) Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol 7(10):1133–1147PubMedCrossRef

16.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef

17.

Rochon PA, Katz JN, Morrow LA et al (1996) Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 34(11):1093–1101PubMedCrossRef

18.

D’Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32(5):382–387PubMed

19.

Pompei P, Charlson ME, Douglas RG Jr (1988) Clinical assessments as predictors of one year survival after hospitalization: implications for prognostic stratification. J Clin Epidemiol 41(3):275–284PubMedCrossRef

20.

Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 65(9):924–933PubMedCrossRef

21.

Lund L, Jacobsen J, Norgaard M et al (2006) The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. J Urol 182(1):35–40 (discussion 40)CrossRef

22.

Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P (2008) Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 179(3):857–861PubMedCrossRef

23.

Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML (2003) Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 169(4):1282–1286PubMedCrossRef

24.

Berger DA, Megwalu II, Vlahiotis A et al (2008) Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology 72(2):359–363PubMedCentralPubMedCrossRef

25.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20):2441–2447PubMedCrossRef

26.

O’Connor KM, Davis N, Lennon GM, Quinlan DM, Mulvin DW (2009) Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 103(11):1492–1495PubMedCrossRef

27.

Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279PubMedCrossRef

28.

Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3):398–406PubMedCrossRef

29.

Kutikov A, Egleston BL, Wong YN, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28(2):311–317PubMedCentralPubMedCrossRef

30.

Lughezzani G, Sun M, Budaus L, Thuret R, Perrotte P, Karakiewicz PI (2010) Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J Clin Oncol 28(18):e299–e300 (author reply e301)PubMedCrossRef

31.

Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG (2012) Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 188(6):2077–2083PubMedCrossRef

Title: Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death
Authors: David Y. T. Chen
Robert G. Uzzo
Rosalia Viterbo
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 3/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1285-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death

Abstract

Introduction

Materials and methods

Results and Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results and Discussion

Please log in to get access to this content

Other articles of this Issue 3/2014

Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma

Clinical management of renal cell carcinoma with venous tumor thrombus

Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study

The contemporary role on surgery in the management of renal masses

Do robotic prostatectomy positive surgical margins occur in the same location as extraprostatic extension?

The Integral Theory System Questionnaire: an anatomically directed questionnaire to determine pelvic floor dysfunctions in women